Want to see GB:HEMO full AI Analyst Report?
HEMO Stock Chart & Stats
568.00 p
-12.50 p(-3.23%)
At close: 4:00 PM EST
568.00 p
-12.50 p(-3.23%)
Day’s Range― - ―
52-Week Range130.00 p - 1,800.00 p
Previous CloseN/A
Volume114.00
Average Volume (3M)113.41K
Market Cap
£53.38M
Enterprise Value53.32M
Total Cash (Recent Filing)£1.59M
Total Debt (Recent Filing)£2.00M
Price to Earnings (P/E)―
Beta0.31
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.21
Shares Outstanding6,799,961
10 Day Avg. Volume30,447
30 Day Avg. Volume113,406
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)21.26
Price to Sales (P/S)0.00
P/FCF Ratio-7.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Hematology/oncology PipelineA clear therapeutic focus on hematology and oncology creates durable domain expertise and platform synergies. Specialization supports deeper clinical know-how, targeted R&D efficiency, and the potential for enduring partnerships or licensing in niche but high-value clinical segments.
Lean Organizational StructureA small headcount implies a lean operating model that can reduce fixed costs and extend runway for a pre-revenue biotech. Conserved overhead supports sustained R&D activity on limited capital, improving chances to reach clinical inflection points before large commercial scale-up.
Reduction In Absolute Debt LevelsFalling nominal debt lessens interest and refinancing load, improving financial flexibility over months. For a loss-making, pre-revenue company, any deleveraging reduces near-term financing pressure and supports longer runway to advance clinical programs or secure strategic partnerships.
Bears Say
Pre-revenue ProfileAbsence of product revenue means the company depends on external funding or milestones to continue operations. This limits visibility into sustainable margins and commercial viability, raising long-term execution risk until clinical assets translate into recurring sales or licensing income.
Persistent Negative Operating And Free Cash FlowOngoing negative operating and free cash flow indicate structural cash burn requiring repeated financing. Over months this elevates dilution risk, increases dependence on capital markets or partners, and constrains the company's ability to fund trials or scale without strategic transactions.
Widening Net Losses And Diminished Equity BufferSharply larger losses and a shrinking equity base reduce the balance-sheet cushion against setbacks. This elevates insolvency and refinancing risk over time, making the company more vulnerable to trials failing, delays, or unfavorable funding terms that could impair long-term program execution.
HemoGenyx Pharmaceuticals Plc News
HEMO FAQ
What was HemoGenyx Pharmaceuticals Plc’s price range in the past 12 months?
HemoGenyx Pharmaceuticals Plc lowest share price was 130.00 p and its highest was 1800.00 p in the past 12 months.
What is HemoGenyx Pharmaceuticals Plc’s market cap?
HemoGenyx Pharmaceuticals Plc’s market cap is £53.38M.
When is HemoGenyx Pharmaceuticals Plc’s upcoming earnings report date?
HemoGenyx Pharmaceuticals Plc’s upcoming earnings report date is Sep 24, 2026 which is in 64 days.
How were HemoGenyx Pharmaceuticals Plc’s earnings last quarter?
HemoGenyx Pharmaceuticals Plc released its earnings results on Apr 30, 2026. The company reported -0.787 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.787 p.
Is HemoGenyx Pharmaceuticals Plc overvalued?
According to Wall Street analysts HemoGenyx Pharmaceuticals Plc’s price is currently Overvalued.
Does HemoGenyx Pharmaceuticals Plc pay dividends?
HemoGenyx Pharmaceuticals Plc does not currently pay dividends.
What is HemoGenyx Pharmaceuticals Plc’s EPS estimate?
HemoGenyx Pharmaceuticals Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does HemoGenyx Pharmaceuticals Plc have?
HemoGenyx Pharmaceuticals Plc has 6,799,961 shares outstanding.
What happened to HemoGenyx Pharmaceuticals Plc’s price movement after its last earnings report?
HemoGenyx Pharmaceuticals Plc reported an EPS of -0.787 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.735%.
Which hedge fund is a major shareholder of HemoGenyx Pharmaceuticals Plc?
Currently, no hedge funds are holding shares in GB:HEMO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HemoGenyx Pharmaceuticals Plc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
117.23%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-0.85%
Trailing 12-Months
Company Description
HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc is a preclinical biotechnology company dedicated to the discovery, advancement, and commercialization of innovative therapies for various blood diseases. The firm's pipeline is heavily focused on creating novel solutions for the bone marrow and hematopoietic stem cell (BM/HSC) transplant sector. Key developments include a CDX bi-specific antibody, engineered to target challenging conditions such as relapsed/refractory acute myeloid leukaemia (R/R AML), specific forms of acute lymphoblastic leukaemia, and myelodysplastic syndrome, aiming to replace traditional chemotherapy or radiation for transplant conditioning. Also under development is HEMO-CAR-T therapy, which utilizes chimeric antigen receptor T-cells to effectively identify and destroy human acute myeloid leukaemia cells in laboratory and in vivo settings. Additionally, the company is advancing Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapeutic specifically for BM/HSC transplant procedures. Founded in 2012, Hemogenyx Pharmaceuticals is headquartered in London, United Kingdom.
Technical Analysis
ImmuPharma
―
Open Orphan Plc
―
Poolbeg Pharma Ltd.
―
Arecor Therapeutics PLC
―
Aptamer Group Plc
―